All the Drug Class Drugs
IgG4 Monoclonal Antibody. Nivolumab 10 mg/ml. VIALS (IV infus.).: 4ml, 10ml. 3 mg/kg
admin. as an IV infuse. over 60 min. every 2 wks. until dis. progress. or unaccept. toxicity. See lit.
Tmt. of pts. with advanced (unresect., metastatic) melanoma in adults. - As monotherapy and in combination with ipilimumab.
Tmt. of advanc. (unresect./metastat.) melanoma in adult.
In comb. with ipilimumab, is indic. for the tmt. of pts. with advanc. (unresect./metast.) melanoma.
Tmt. of pts. with metast. NSCLC with progres. on or after plat.-based chemother.
Tmt. of pts. with advance. renal cell carcin.(RCC) who have receiv. prior anti-angiog. ther.
Tmt. of pts. classic. Hodgkin lymph. (cHL) that has relapsed or progres. after autologous hematopoiet. stem cell transplant. (HSCT) & post transplant. brentuximab vedotin.
Tmt. of pts. with recur./metast. squam. cell carcin. of the head & neck (SCCHN) with dis. progres. on or after plat. based ther.
Tmt. of adut. & ped. pts. 12 yrs. & old. with microsatellite instabil.-high (MSI-H) or mismatch repair defic. (dMMR) metast. colorect. cancer (CRC) that has progres. follow. tmt. with a fluoropyrimidine, oxaliplatin, & irinotecan.
Tmt. of pts. with local. advance. or metast. urothelial carcin. who: Have dis. progres. during or follow. plat.-contain. chemother.
Have dis. progres. within 12 mnths. of neoadjuvant or adjuv. tmt. with plat. contain. chemother.
Tmt. of pts. with hepatocel. carcin. Child-Pugh A after sorafenib ther.
C/I: Hypersens.
IgG4 Monoclonal Antibody. Nivolumab 12 mg/ml, Relatlimab 4 mg/ml. 12 mg nivolumab+ 4 mg relatlimab/ml
Conc. for sol. for IV,1 X 20 ml
480 mg nivolumab and 160 mg relatlimab every 4 weeks as IV over 30 min. For adlts. and ped. pts 12 years and older weighing at least 30 kg
Tmt. of adlt and ped. pts. 12 years or older with unresect. or metast. melanoma
C/I:Hypersens
